Health Care • Biotechnology: Pharmaceutical Preparations
$6.49 ▼ -0.26
(-3.85%)
MKT CAP: $204.2M • VOL: 78.8K
52W L $6 52W H $11
RNAC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $400.0K | $38.3M | $26.0M |
| YoY Revenue Growth % | -99.0% | +47.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$143.4M | -$43.9M | -$86.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$130.3M | -$77.4M | -$219.7M |
| EBITDA (Normalized) | -$139.0M | -$36.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$73.9M | -$23.7M | -$51.2M |
| Capital Expenditures (CapEx) | $5.5M | $9.1M | — |
| Free Cash Flow (FCF) | -$79.4M | -$32.8M | -$51.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $125.1M | $212.6M | — |
| Total Debt (Short + Long Term) | $0 | — | — |
| Total Stockholders' Equity | -$126.2M | -$6.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RNAC.